TCS Join Forces with Dassault Systems To Create Digital Human Heart Models

Tata Consultancy Services (TCS) the tech giant and IT service provider has collaborated with the European technology major Dassault Systems to contribute to Living Heart Project. This particular partnership aims to develop precise digital models of the human heart marking a significant milestone in medical research and technology.

TCS Digital BioTwin is a state-of-the-art computational model designed to enhance the remote and non-invasive study of the human heart's function.TCS has revealed its commitment to utilizing its domain knowledge, technological expertise, and research on Digital BioTwin of the heart to enhance the accuracy and personalization of digital human heart models.

The Living Heart Project is supposed to serve as an inclusive platform, that will bring cardiovascular researchers, educators, medical device developers, regulatory agencies such as the US Food and Drug Administration (FDA), and practicing cardiologists together. These all participants will share a common goal to create and validate realistic digital simulations of the human heart.

“We are delighted to welcome Tata Consultancy Services to our Living Heart Project,” said Steve Levine, Sr. Director, Virtual Human Modeling, Dassault Systèmes and founder of The Living Heart Project, “Their deep expertise in research and technology development will bring invaluable insights to our mission and to others in the field. This collaboration demonstrates our shared commitment to leveraging the virtual world for the advancement of medical science and patient care. By joining forces, we believe we can accelerate the pace of innovation and make significant strides towards our goal of creating and delivering personalized in-silico medical solutions.”

TCS is excited to be a part of the Living Heart initiative, and to collaborate in creating a pathbreaking digital simulation of the human heart that can enrich our understanding of the cardiac function and provide insights for novel cardiac treatments and new product development for the med-tech and pharma sectors. We believe that our extensive expertise in building digital bio-twins for other organs and body parts positions us well to contribute significantly to this collaborative initiative,” said Vikram Karakoti, Business Head, Life Sciences, TCS.

One of the key aspects of this collaboration is the potential use of heart simulations as a piece of digital evidence for the approval of new cardiovascular devices. They will test and refine medical devices in the virtual realm before conducting a real-world trial. The project is dedicated to the enhancement of safety and effectiveness while expediting the development process.